Phase Holographic Imaging receives significant order

Phase Holographic Imaging (PHI) has received a follow-up order for a minimum of eight motorized HoloMonitor M4 instruments, continuing the strong business performance in the Chinese market. The total customer list price of the ordered instruments amounts to 2.8 MSEK. The instruments will be delivered to PHI’s Chinese distributor during the coming 12 months on a continuous basis.

“This order from our Chinese distributor gives us a very nice revenue baseline for the fiscal year 2016/17 that began in May”, said CEO Peter Egelberg.

For additional information, please contact:

Peter Egelberg, CEO

Tel: +46 703 19 42 74

E-mail: peter.egelberg@phiab.se

Web: www.phiab.se

Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Headquartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.

About Us

Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first HoloMonitor instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Head-quartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.

Subscribe

Documents & Links